Motley Fool Money - The Great Rule Breakers Healthcare Debate: Progyny or Hims & Hers?

Episode Date: September 22, 2025

Which is the better healthcare Breaker? Alicia Alfiere, Sanmeet Deo, and Tim Beyers pit Progyny against Hims & Hers. Leave a comment to get in on the debate! Alicia Alfiere, Sanmeet Deo, and Tim Beyers discuss: - Progyny vs. Hims & Hers - who goes on the watchlist? - Intel and NVIDIA’s big $5 billion deal. - Reflections on Rule Breaker Investing. Be sure to get to your local bookstore and pick up a copy of David’s Gardner’s new book — Rule Breaker Investing. It’s on shelves now; get it before it’s gone! Companies discussed: PGNY, HIMS, INTC, NVDA Host: Tim Beyers Guests: Alicia Alfiere, Sanmeet Deo Producer: Anand Chokkavelu Engineer: Dan Boyd Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We’re committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit ⁠⁠⁠⁠⁠⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

Which is the better healthcare breaker? Progeny or hymns and hers? Welcome to Botley Fool Money. Good morning. I am your host, Tim Byers. With me are two of my favorite fools, San Mateo and Alicia Alfieri from the rule breakers team. We're going to do a small debate here. And the way this is going to work, fools, is that I am going to ask you to make your case,

First for Progeny, then for Hims and Hers. I'm going to ask you a follow-up question, each of you, and then I'm going to make a call on which one is going on my watch list. So the audience is your audience, but also I am your audience. So you've got to convince me. So, Alicia, make the case. Why do I want to be invested in Progeny? Okay.

So Progeny is essentially a health benefit that employers provide as part of their overall benefits package. Think of it like a super customer-focused health benefit, including drug coverage for fertility and family building. So infertility is a migraine level problem that roughly one in six people of reproductive age experience, it's also an expensive problem. So depending on where you live,

a single round of IVF can cost $10,000 to $20,000 or more, and that might not even include medication. Prior to companies like progeny, if fertility services, were covered by insurance, it could be restrictive with lifetime dollar maximums and things like mandated step therapy, which was expensive, wasted time, and wasn't a personalized approach. So of the six signs of a rule breaker, progeny has about, we'll say three and a half. The most important part, I think, is their sustainable advantage. They have a strong brand power

in an excellent network with great clinical outcomes. They have a strong brand in the core market. They're expanding into services like pregnancy support and menopause care. It also has an impressive network of fertility specialists across the U.S. that really deliver impressive results by harnessing expertise and data. So, for example, within progenies network, there's a 21% lower miscarriage rate, a 23% higher live birth rate, and it takes 1.5 fewer retrievals per live birth. So better results, more efficient, and as a result, less. costly. So this is a much better suite of services for those who are dealing with infertility.

This is, you know, essentially the argument for progeny is if you just go for in vitro fertilization without the aid of progeny, your outcomes might not be as good. Single follow-up question for you here. They work with providers, and they don't necessarily work with insurers here. They work with companies that provide this benefit, and they do have some customer concentration, Alicia, and they've lost some customers, some big customers. So how can this company grow sustainably, despite how good the outcomes are based on their data? This is an excellent question. So they did lose one major customer last year, and it did impact the companies. revenue, something like 12 to 13%. Now, they do have over 500 clients so they can continue to grow

by continuing to grow the number of clients that they serve and the number of covered lives or the people that are covered under their services. They can also do more optionality. So I mentioned they expanded into menopause care and pregnancy services. So they can continue to grow in their optionality for different women's care services. All right, Sam, meet. So, ticker for progeny, PGNY, PGNY, that's progeny. We are moving over to Hems and hers, ticker H-I-M-S. All right, give it to me.

Why do I want this one? All right. So Hems and Hers is really exactly the kind of rule-breaking platform company I look for personally. You know, it's delivering rapid growth, recurring revenue, improving margins. It has a relentless expansion into huge new markets. So they're not just writing a trend. They're building a modern healthcare brand for the next generation with technology and customer experience at the core.

So there's several factors here. First is their breakneck growth. They've been growing 40% year over year in a healthcare sector, which is quite fast. And all of it's being driven by customer acquisition and high retention rates. They have recurring revenue because the customers that they get are paying subscriptions for the products and services that they get. Another appealing aspect is they have a strong, consumer appeal brand and user experience.

They're attracting a lot of the millennials in Gen Z who don't want to go into doctor's office, especially for stigma-type conditions. So, you know, they're meeting those customers online, on phones, so they can get treatments for things like mental health, hair loss, weight management, and now they're expanding into even things like hormonal health care. Don't forget the hers brand, which also does a lot of, will also be doing. some menopause treatments in the future. So I think also HEMS has a massive addressable market opportunity.

I mean, and optionality. I mean, they're in already multiple areas that could develop into, you know, billion-dollar brands when it comes to, you know, some of the things that I talked about before, but they've also been scaling. They just launched into men's hormones. They're looking into, you know, female menopause, also looking at longevity. And those are all on their radar. to kind of expand into. And finally, the biggest thing is technology and profitability. They're

bringing technology into healthcare where it's severely lacked, and it's difficult. It's not easy by any means, but they've created a platform that has been easy to use. And now they're just at that inflection point of profitability. They're earnings profitable in the past fiscal year, and they're looking to expand on that. I mean, you mentioned the technology. piece of this. A lot of this interaction with the Hems and Hers brand is via mobile app, which is, I mean, it's not like we are seeing this in other places. So it's not like that's completely novel, but I do concede that that is interesting. But you mentioned something about, I mean, Samit, you say, we're getting into the hormone business. That sounds like, the FDA might have

something to say about that. So can we talk about regulatory, risk here? Like, what's going on here? How do they deal with regulators? I mean, absolutely. Regulatory risk is probably one of the biggest risk factors in this company. And, you know, you don't want to wake up the next morning holding your hemstock and see some big thing come down from the government. But, you know, they're doing the things that they need to do to kind of keep that manageable. You know, they have a robust compliance team. They've hired former regulators on their team to kind of keep them in compliance with some, some, some, some, some regulators' laws. And they've been, from what I've seen also very quick to make changes and adjustments to their

platform, to their, to their, to their, to their products when it seems like, you know, the, the, the federal government or the FDA is kind of clamping down on them. And they've bought facilities that are, you know, within, you know, within compliance. and also, you know, they're doing the things that they need to do to stay in the good graces. I mean, it's interesting. So, fools, we want to hear from you. Which of these two do you want on your watch list? I'm going to tell you right now that my choice for this is progeny.

And the reason why, Sandmeet, is because that regulatory risk feels pretty existential to me. And we have an activist federal government right now. without making this political in any way, this government has decided to make big sweeping moves faster than anybody anticipated. And that, for Hems and hers, that could be significant in ways that I can't predict. But I like both of these. And I think you both have made a compelling argument for why they are potential breakers in the making. But fools, we want to know what you think. Get your comments in. Let us know what you want. And if you have a strong case for hymns and hers, let's hear it. You know, back them up. Just because I back progeny, it doesn't mean I'm right.

So let's hear about it. All right. Up next, Intel and Nvidia, get cuddly. How should investors respond to this deal between these two? You're listening to Motley Full Money. Some of the best lessons don't come from a classroom. They come from experience. On the power of advice, a new podcast series from Capital Group, you'll hear from CEOs, investors, and founders about how they built careers, took risks, and reinvented themselves. If you're starting your own journey, this is the kind of advice you won't want to miss.

Available wherever you get your podcast, published by Capital Client Group, Inc. All right, fools, let's talk about Intel and Nvidia. Nvidia. Invidia is investing $5 billion in Intel stock at $23.28 a share. This is a private placement. And the difference between investing on the open market and a private placement is that Intel is selling stock directly to Nvidia, and thus they are getting the $5 billion to put on their balance sheet and deploy as capital for growing their business. It's a real interesting one. The deal between the two will include work on both data, Center and personal computing products.

I have a take on this, but I would like to go to you first here, Sandmeet, just at the highest level, hearing that Intel and Nvidia are going to work both in the data center and on personal computing products. What is your reaction? I mean, I think it's great. I think they're both, you know, really helping each other out. You know, Intel has a lot of the infrastructure and the facilities to create. the chips that go into CPUs, that's not something Nvidia's been an expert in.

They're experts in the GPU sets. So being able to co-design products when it comes to data center and the PCs is going to be helpful for both of them. So they're kind of helping each other out. I mean, Alicia, where do you stand on this? Because, I mean, Sammy's right. Nvidia doesn't necessarily have expertise making. And we can talk a little bit more about this.

I'll explain the details, but central processing units, which are kind of of like, in the picture of an orchestra, if the GPU is the great sound system, the CPU is the conductor at the front of the orchestra that makes all the sound come together, and then the sound system amplifies that. I mean, how do you feel about this deal? Yeah, well, I'm going to say, I think that Nvidia actually benefits more. So certainly the cash infusion and the product partnerships. help Intel, but Nvidia is the one with all of the power in this relationship.

And now they get a stake in a partner as well. Also, I think for me to really call this in favor of Intel, I think I would need it to really benefit their foundry business. That's just my take. But what do you think? No, I think that's fair. And for those who don't know, so Intel is competing with Taiwan Semiconductor to take other people's designs and manufacture those chips. And they have really not done a great job of scaling

that business. Taiwan Semi is far in a way the dominant provider in this part of the business. So that's a real question. Like, does that $5 billion go into building out the foundry business? So we actually manufacture more chips on American shores. We know that's something this administration wants. But for me, I look at this and see what Sandmeet's. said about invidia getting into the CPU business through the backdoor is pretty interesting because invidia does want to sell whole systems, particularly at data center scale. And in order to sell whole systems, you do have to have, again, no such thing as an orchestra if you don't have an orchestrator, if you don't have a conductor, and you need that CPU.

you. So I do think that is meaningful for Nvidia. But I also think you're right about this, you know, like, who has the power in this relationship? I think we know. It's the one with the big checkbook. We know who has the power in this relationship. So for me, I do think it's a bigger deal for Intel in terms of potential value creation. But in terms of strategic fit, there's a lot to like about this from Nvidia's perspective. But if I'm going to make a buy call just based solely on this deal, this does not make me want to buy Nvidia more, but it might make me want to at least move Intel onto the watch list. And that is in some ways a reflection of the valuation delta between the two.

All right. Up next, a bit of reflections on rules. breaker investing and David Gardner's new book. The old adage goes, it isn't what you say, it's how you say it, because to truly make an impact, you need to set an example and take the lead. You have to adapt to whatever comes your way. When you're that driven, you drive an equally determined vehicle, the Range Rover Sport. The Range Rover Sport blends power, poise, and performance. Its design is distinctly British and free from unnecessary details, allowing its raw agility to shine through. It combines a dynamic

sporting personality with elegance to deliver a truly instinctive drive. Inside, you'll find true modern luxury with the latest innovations in comfort. Use the cabin air purification system alongside active noise cancellation for all new levels of quality and quiet. Whether you prefer a choice of powerful engines or the plug-in hybrid with an estimated range of 53 miles, there's an option for you. With seven terrain modes to choose from, terrain response two fine-tuned your vehicle for the roads ahead. The Rangerover event is on now. Explore Enhance Offers at rangerover.com. All right, fools, if you haven't seen it yet last week, David Gardner, our co-founder at the Motley Fool, our chief rulebreaker, released a new book, which he is calling Rule Breaker Investing.

You may have seen the iconic green cover already. It looks great. And it is a reflection of the principles of Rule Breaker investing along three different areas. the habits of a rule breaker investor, six traits of a rule breaking stock, and then the elements of rule breaking portfolio management. So it's a very comprehensive book. It includes all the learnings that David has had over like 30 years plus of investing at the Motley Fool. And even before that and actually building out his rule breakers philosophy, we're each going to give a little bit of a story about how that philosophy has impacted us. And I think, Alicia, I wouldn't mind starting with you. How do you think about rule breakers investing, you know,

the philosophy and what David's captured in this book? Yeah. I think for me, the part of our ethos that I've really keyed in on over the last few years, I did start during the height of the pandemic bubble. Yeah, I remember. Right. And so I think the part that I've really keyed on as a result is the overvalued by financial media part. And it's important to realize that it's more than just picking a company that's price to perfection or price beyond perfection and thinking, hey, you only live once. It's about finding compelling companies and those that have price dislocated.

And so what I mean by that is a company that might be misunderstood by the market has some kind of optionality that is coming in the future that maybe the market is missing or is not giving ample credit to or has a short-term challenge, also known as dark clouds that we can see through. And I think for me, that's really been where the beauty is in working through rule breakers. I like it. Sam, me, how about yourself? Yeah, you know, so I think the rule breakers, I've worked on Wall Street. And so I've been exposed to value investing and growth investing. You know, as you start investing and learning on your own, you kind of fall into the strategy that works best for your own personality. And Rule Breaker seems to really fit my personality and my style, because a couple of the signs is consumer appeal and overvalued.

Because the kinds of companies I really like and enjoy, you know, researching, picking, tend to fall into those two brackets. I mean, when you have like a Netflix and a Chipotle and all these companies that have such strong consumer appeal, you see them every day. I find Rule Ricker investing to be observational investing. You're looking around in the world, seeing what's happening and seeing if that's an investment opportunity. But these stocks don't tend to be very cheaply valued for a reason.

So this strategy kind of says, hey, it's okay to buy overvalued stocks. Why are they overvalued? Because they're winning. And you want to buy more of these winners as they grow and as they continue to make an impact in the world. So that's one of the most appealing parts about RUricks investing that have, have adopted. I like it. Well, I'll just close us out here and say I've spent the last 20 plus years learning to become a better investor as a member of the Rule Breakers team. I started on the Rule Breakers team in April 2005. Rule Breakers started in October of 2004. So we are about to hit

21 years. I mean, it's bonkers. I can barely believe it. Working with David, Rick, Carl, you know, you, Alicia, Tom, so many others. It's been the greatest privilege of my professional life, to be sure. And as I've grown in the role, David has helped me to see how my own expertise and insights could be honed through the lens of making my portfolio reflect my best vision for the world, which to this day remains one of the most important principles of rule breaker investing. It's something David talks about extensive. in the book, and it certainly led me to focusing on the most painful problems I could find. I'm a tech investor, so I tend to look for painful tech problems and then investing in the ones that

are providing relief. I have to tell you, the life-changing returns I've achieved as a result of that are a gift that I will never be able to fully repay to David. So I'm very grateful for this book. It's been a great ride. And two decades on, I'm still getting smarter, happier, and richer. Not every day, you know, maybe two out of three most days. I'm not getting richer every single day. That is not true. The market does not cooperate in that way. But it's been a great ride. And I'm very grateful for David. I'm very grateful for the book. I'm grateful for Tom and David starting the Motley Fool. I've learned a lot. I mean, one of these days, we're going to do a tribute to Tom Gardner, too, and it's going to be just as eloquent because he's been just as

important to the growth and development of the Motley Fool. I mean, the two of them together have just been unstoppable and it's been great. So enough with heaping on the praise for our bosses, but we do love them because they have been really great to us. And Rule Breaker investing really has been a gift to us here, who are employees of the Motley Fool who have worked closely with both Tom and David. And now David's released this book into the world. And so it can be something that benefits you. So we hope you give it a read. Pick it up, give it a read. I think it's worth your time. But that's it for today's show. Thank you for tuning in to Motley Fool money. As always, people on the program may have interest in the stocks they talk about, and the Motley Fool

may have formal recommendations for or against, so don't buy or sell stocks based solely on what you hear. All personal finance content follows, Motley Fool editorial standards and is not approved by advertisers. Advertisements are sponsored content and provided for informational purposes only. To see our full advertising disclosure, please check out our show notes. For Alicia Alfieri, Sam McDeo, for our engineer, Dan Boyd and our producer, Anna and Chakapaloo. I'm Tim Byers. Thank you for tuning in, Fools.

We will see you again tomorrow when Emily is going to be talking some small caps. And you're going to want to pay attention to that. So stay tuned. We'll see you again, fools. Bluant.